# Bioresorbable Glass Fiber Matrix in the Treatment of Diabetic Foot Ulcers

> **NCT06403605** · NA · COMPLETED · sponsor: **ETS Wound Care, LLC** · enrollment: 148 (actual)

## Conditions studied

- Diabetic Foot Ulcer
- Ulcer Foot
- Diabetic Foot

## Interventions

- **DEVICE:** Mirragen Advanced Wound Matrix
- **DEVICE:** Fibracol

## Key facts

- **NCT ID:** NCT06403605
- **Lead sponsor:** ETS Wound Care, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-09-13
- **Primary completion:** 2025-01-17
- **Final completion:** 2025-01-17
- **Target enrollment:** 148 (ACTUAL)
- **Last updated:** 2025-11-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06403605

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06403605, "Bioresorbable Glass Fiber Matrix in the Treatment of Diabetic Foot Ulcers". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06403605. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*